



No. 14-158010- -00001-0000

Fecha: 2014-07-22 09:26:33 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 608 MODIFICASOLICIT Folios: 47

DIRECCIÓN DE NUEVAS CREACIONES
MODIFICACIONES Y/O CORRECCIONES

1. Identificación del Trámite

☐ Error material

☒ Modificación a una Solicitud en trámite

☒ Patente de Invención

☐ Patente de Modelo de Utilidad

☐ Registro de Diseño Industrial

☐ Esquema de Trazado de Circuitos Integrados

2. Datos del solicitante

Persona Natural ☐

Persona Jurídica ☒

CONNEXIOS LIFE SCIENCES PVT. LTD.

Nombre o denominación / Nombre o razón social completa

Nombre representante legal

Tipo de empresa

Micro ☐

Pequeña ☐

Mediana ☐

Otra ☒

Documento de identificación:

☐ C.C.

☐ C.E.

☐ NIT

☒ Otro Número

Nacionalidad/País de constitución	Dirección y domicilio del titular	Ciudad
India	No.49, Shilpa Vidya, First Main Road, J P Nagar 3rd Phase	Bangalore
Dirección electrónica	No. Fax	Número telefónico
tobos@tobos.com.co	571 8123335	571 8123335

☒

Autorizo expresamente a la Superintendencia de Industria y Comercio para que todas las comunicaciones sean enviadas a través de la dirección de correo electrónico

3. Datos del apoderado:

TOBOS MATEUS Andrea

52.223.325

148.648

Apellidos y Nombre

Documento de identificación

Tarjeta profesional

Dirección y domicilio	Ciudad	
Carrera 7 C No. 138 -19 Oficina 901	Bogotá, D.C. Colombia	
Dirección electrónica	No. Fax	Número telefónico
andrea.tobos@tobos.com.co	571 8123335	571 8123335

En caso de haber presentado poder general para asuntos que se adelanten ante la Delegatura de Propiedad Industrial, sírvase indicar el número de su radicación o protocolo de poder general

4. Datos del trámite

Corrección:

Expediente No 14-158010

Aparece _____

Debe ser _____

Modificación:

☒ Modificación al capítulo reivindicatorio.
El solicitante desea limitar el Capítulo Reivindicatorio de 30 reivindicaciones a 26 reivindicaciones.

☐ Modificación al capítulo descriptivo.

☐ Modificación al resumen.

☐ Modificación a los dibujos.

☐ Modificación al solicitante.

5. Anexos

☒ Comprobante de pago de la tasa para la presentación de la corrección y/o modificación

☐ Poder, si fuere el caso.

☐ Documento que contiene las modificaciones o correcciones.


☐ Copia de la solicitud y sus anexos en formato magnético.

6. Firma

ANDREA TOBOS MATEUS

Nombre y apellidos

C.C 52.223.325




Firma

Tarjeta Profesional 148.648

REIVINDICACIONES

1. Un compuesto de la fórmula (I):

5



Fórmula (I)

caracterizado porque:

10


cada R^1 y R^{1a} es independientemente seleccionado del grupo que consiste de H, metilo, $\text{CONHC}(\text{CH}_3)_3$, OH, CO_2H , CO_2CH_3 , $\text{CO}_2\text{CH}_2\text{CH}_3$, fenilo, CH_2OH , CN y OCH_3 .

15

o cualquiera dos R^1 en átomos de carbono adyacentes se puede unir para formar una fracción cíclica, o cualquiera dos R^1 en el mismo carbono cuando se toman juntos pueden formar un grupo de la fórmula $=\text{O}$.

Ar es una opcionalmente sustituida por grupo c1-C_{18} heteroarilo;


20



25

390

y



5 en donde cada R^7 es independientemente
 seleccionado del grupo que consiste H, halógeno, OH, NO₂,
 CN, SH, NH₂, CF₃, OCF₃, opcionalmente sustituido C₁-
 C₁₂alquilo, opcionalmente sustituido C₁-C₁₂haloalquilo,
 10 opcionalmente sustituido C₂-C₁₂alquenilo, opcionalmente
 sustituido C₂-C₁₂alquinilo, opcionalmente sustituido C₂-
 C₁₂heteroalquilo, opcionalmente sustituido C₃-
 C₁₂cicloalquilo, opcionalmente sustituido C₃-
 C₁₂cicloalquenilo, opcionalmente sustituido C₂-
 C₁₂heterocicloalquilo, opcionalmente sustituido C₂-
 15 C₁₂heterocicloalquenilo, opcionalmente sustituido C₆-
 C₁₈arilo, opcionalmente sustituido C₁- C₁₈heteroarilo,
 opcionalmente sustituido C₁-C₁₂alquiloxi, opcionalmente
 sustituido C₂-C₁₂alquenilooxi, opcionalmente sustituido C₂-
 20 C₁₂alquinilooxi, opcionalmente sustituido C₂-
 C₁₀heteroalquiloxi, opcionalmente sustituido C₃-
 C₁₂cicloalquiloxi, opcionalmente sustituido C₃-
 C₁₂cicloalquenilooxi, opcionalmente sustituido C₂-
 C₁₂heterocicloalquiloxi, opcionalmente sustituido C₂-C₁₂
 heterocicloalquenilooxi, opcionalmente sustituido C₆-
 25 C₁₈arilooxi, opcionalmente sustituido C₁-C₁ heteroarilooxi,

391

opcionalmente sustituido C₁-C₁₂alquiloamino, SR⁹, SO₃H, SO₂NR⁹R¹⁰, SO₂R⁹, SONR⁹R¹⁰, SOR⁹, COR⁹, COOH, COOR⁹, CONR⁹R¹⁰, NR⁹COR¹⁰, NR⁹COOR¹⁰, NR⁹SO₂R¹⁰, NR⁹CONR⁹R¹⁰, NR⁹R¹⁰, y acil;

5 en donde R⁸ es seleccionado del grupo que
consiste en H, opcionalmente sustituido C₁- C₁₂alquilo,
opcionalmente sustituido C₂-C₁₂alquenilo, opcionalmente
sustituido C₂-C₁₂alquinilo, opcionalmente sustituido C₂-
C₁₂heteroalquilo, opcionalmente sustituido C₃-
C₁₂cicloalquilo, opcionalmente sustituido C₂-
10 C₁₂heterocicloalquilo, opcionalmente sustituido C₆-C₁₈arilo,
opcionalmente sustituido C₁- C₁₈heteroarilo, SO₃H, SO₂NR⁹R¹⁰,
SO₂R⁹, SONR⁹R¹⁰, SOR⁹, COR⁹, COOH, COOR⁹, y CONR⁹R¹⁰;

 en donde cada R⁹ y R¹⁰ es independientemente
seleccionado del grupo que consiste en H, opcionalmente
15 sustituido C₁-C₁₂alquilo, opcionalmente sustituido C₂-
C₁₀heteroalquilo, opcionalmente sustituido C₁-C₁₂haloalquilo,
opcionalmente sustituido C₃-C₁₂cicloalquilo, opcionalmente
sustituido C₆- C₁₈arilo, y opcionalmente sustituido C₁-
C₁₈heteroarilo.

20 e es un entero seleccionado del grupo que
consiste de 0, 1, 2, 3 y 4;

 f es un entero seleccionado del grupo que
consiste de 0, 1, 2, y 3;

25

392

A es $-\text{CR}^{\text{a}}\text{R}^{\text{b}}-$;

B es un grupo de la fórmula $-(\text{CR}^{\text{c}}\text{R}^{\text{d}})_n-$;

en donde cada R^{a} , R^{b} , R^{c} y R^{d} es
 independientemente seleccionado del grupo que consiste en
 5 H, halógeno, OH, NO_2 , CN, SH, NH_2 , CF_3 , OCF_3 , opcionalmente
 sustituido C_1 - C_{12} alquilo, opcionalmente sustituido C_2 -
 C_{10} heteroalquilo, opcionalmente sustituido C_1 - C_{12} haloalquilo,
 opcionalmente sustituido C_3 - C_{12} cicloalquilo, opcionalmente
 sustituido C_6 - C_{18} arilo, opcionalmente sustituido C_1 -
 10 C_{18} heteroarilo; SR^2 , SO_3H , $\text{SO}_2\text{NR}^2\text{R}^3$, SO_2R^2 , SONR^2R^3 , SOR^2 ,
 COR^2 , COOH , COOR^2 , CONR^2R^3 , NR^2COR^3 , NR^2COOR^3 , $\text{NR}^2\text{SO}_2\text{R}^3$,
 $\text{NR}^2\text{CONR}^2\text{R}^3$, NR^2R^3 , y acil,

en donde cada R^2 y R^3 es independientemente
 seleccionado del grupo que consiste en H, opcionalmente
 15 sustituido C_1 - C_{12} alquilo, opcionalmente sustituido C_2 -
 C_{10} heteroalquilo, opcionalmente sustituido C_1 - C_{12} haloalquilo,
 opcionalmente sustituido C_3 - C_{12} cicloalquilo, opcionalmente
 sustituido C_6 - C_{18} arilo, y opcionalmente sustituido C_1 -
 C_{18} heteroarilo;

20 W^1 y W^2 están seleccionados de tal forma que uno
 es N y el otro es (CR^1_2) ,

el enlace del carbono carbonil se une a
 cualquiera de W^1 o W^2 es N;

D es O o (CR^1_2) ;

393

n es un entero seleccionado del grupo que
consiste de 0, 1, 2, 3, y 4;

a es un entero seleccionado del grupo que
consiste de 0, 1, y 2;

5

b es un entero seleccionado del grupo que
consiste de 0, 1, 2, 3, 4, 5, 6, 7, y 8,

c es 1;

o una sal farmacéuticamente aceptable de los
mismos.

10

2. Un compuesto de conformidad con la
reivindicación 1, caracterizado porque D es (CR^1_2) .


3. Un compuesto de conformidad con la
reivindicación 1, caracterizado porque B es CH_2 .

15

4. Un compuesto de conformidad con la
reivindicación 1 a 3, caracterizado porque R^a y R^b son
diferentes.

5. Un compuesto de conformidad con la
reivindicación 1 que tiene la fórmula:

20



25

394

en donde Ar, R^a, R^b, R¹, R^{1a}, a y b son como se definen en la reivindicación 1.



6. Un compuesto de conformidad con la reivindicación 5, en donde uno de R^a y R^b es H y el otro es alquilo opcionalmente sustituido.

7. Un compuesto de conformidad con la reivindicación 1, caracterizado porque el sustituyente R⁷ está ubicado en la posición 4 o en la posición 5 del anillo de seis miembros.

8. Un compuesto de conformidad con la reivindicación 1, caracterizado porque R⁷ se selecciona del grupo que consiste de CH₃, CH₂CH₃, CH₂CH₂CH₃, CH(CH₃)₂, (CH₂)₃CH₃, Cl, Br, F, I OH, NO₂, NH₂, CN, SO₃H, OCH₃, OCH₂CH₂CH₃, CF₃ y OCF₃.

9. Un compuesto de conformidad con la reivindicación 1, seleccionado del grupo que consiste en:



20





25

395





5





10





15



20





25






396



5






10



15




20




25

397


5




10







15



20




25




398


5




10






15



20





25





399



5





10



15





20





25

400



5





10



15





20





25

401





5







10



15





20





25

402




5





10



15




20




25

403





404





405



5





10







15



20





25





406





5





10




15



20





25







407



5





10




15















20



25





408







409





5





10



15





20







25

410





5





10





15



20





25







411





5







10



15




20




25


412



413





414







25

415





5






10



15





20





25

416







5







10



15




20




25


417




418



419





420





421



5





10







15



20





25





422



5





10







15



20





25





423



5





10





15



20





25





424



5







10





15




20



25



425



o su sal farmacéuticamente aceptable.

10. Una composición farmacéutica que incluye un compuesto de conformidad con cualquiera de las reivindicaciones 1 a 9 y un diluyente, excipiente o vehículo farmacéuticamente aceptable.

11. Un método para la prevención o tratamiento de una condición en un mamífero, el método comprendiendo la administración de una cantidad efectiva de un compuesto de conformidad con cualquiera de las reivindicaciones 1 a 9.

12. Un método de conformidad con la

reivindicación 11, caracterizado porque la condición puede ser prevenida o tratada por la inhibición de 11 β -HSD1.

5 13. Un método de conformidad con la reivindicación 12, caracterizado porque la condición se selecciona del grupo que consiste de diabetes, hiperglucemia, baja tolerancia a la glucosa, hiperinsulinemia, hiperlipidemia, hipertrigliceridemia, hipercolesterolemia, dislipidemia, obesidad, obesidad abdominal, glaucoma, hipertensión, aterosclerosis y sus
10 secuelas, retinopatía, nefropatía, neuropatía, miopatía, osteoporosis, osteoartritis, demencia, depresión, enfermedades neurodegenerativas, trastornos psiquiátricos, Enfermedad de Cushing, síndrome de Cushing, enfermedades virales, y enfermedades inflamatorias.

15 14. Un método de conformidad con la reivindicación 13, caracterizado porque la condición es diabetes.

 15. Un método de conformidad con la reivindicación 14, caracterizado porque la condición es
20 diabetes tipo II.

 16. El método de conformidad con la reivindicación 12, caracterizado porque el compuesto se administra en combinación con un adyuvante.

25 17. El método de conformidad con la reivindicación 16, caracterizado porque el adyuvante es

427

seleccionado del grupo que consiste de dipeptidil
peptidasa-IV (DP-IV); (b) agentes sensibilizantes de
insulina; (c) insulina y miméticos de insulina; (d)
sulfonilureas y otros secretagogos de insulina; (e)
5 inhibidores alfa-glucosidasa; (f) GLP-1, análogos GLP-1, y
agonistas receptores de GLP-1; y las combinaciones de los
mismos.

18. El método de conformidad con la
reivindicación 17, caracterizado porque los agentes
10 sensibilizantes de insulina son seleccionados del grupo que
consiste en (i) PPAR-gamma-agonistas, (ii) PPAR-alfa-
agonistas, (iii) PPAR-alfa/gamma-dual agonistas, (iv)
biguanidas, y combinaciones de los mismos.

19. El uso de un compuesto de conformidad con la
15 reivindicación 1 en la preparación de un medicamento.

20. El uso de conformidad con la reivindicación
19, caracterizado porque el medicamento es para el
tratamiento de una condición que se puede prevenir o tratar
por la inhibición de 11 β -HSD1.

21. El uso de conformidad con la reivindicación
20, caracterizado porque la condición se selecciona del
grupo que consiste de diabetes, hiperglucemia, baja
tolerancia a la glucosa, hiperinsulinemia, hiperlipidemia,
hipertrigliceridemia, hipercolesterolemia, dislipidemia,
25 obesidad, obesidad abdominal, glaucoma, hipertensión,

428

aterosclerosis y sus secuelas, retinopatía, nefropatía, neuropatía, miopatía, osteoporosis, osteoartritis, demencia, depresión, enfermedades neurodegenerativa, trastornos psiquiátricos, Enfermedad de Cushing, síndrome
5 de Cushing, enfermedades virales, y enfermedades inflamatorias.

22. Un uso de conformidad con la reivindicación 21, caracterizado porque la condición es diabetes.

23. Un uso de conformidad con la reivindicación
10 22, caracterizado porque la condición es diabetes tipo II.

24. Un uso de conformidad con la reivindicación 22 ó 23, caracterizado porque el medicamento contiene un adyuvante.

25. Un uso de conformidad con la reivindicación
15 24, caracterizado porque el adyuvante es seleccionado del grupo que consiste de dipeptidil peptidasa-IV (DP-IV); (b) agentes sensibilizantes de insulina; (c) insulina y miméticos de insulina; (d) sulfonilureas y otros secretagogos de insulina; (e) inhibidores alfa-glucosidasa;
20 (f) GLP-1, análogos GLP-1, y agonistas receptores de GLP-1; y las combinaciones de los mismos.

26. El uso de conformidad con la reivindicación 25, caracterizado porque los agentes sensibilizantes de insulina son seleccionados del grupo que consiste en (i)
25 PPAR-gamma-agonistas, (ii) PPAR-alfa-agonistas, (iii) PPAR-

429

alfa/gamma-dual agonistas, (iv) biguanidas, y combinaciones de los mismos.

430

RESUMEN

La presente invención se relaciona a ciertos derivados de amida que tienen la capacidad para inhibir 11-
5 β -hidroxiesteroide deshidrogenasa tipo 1 (11β -HSD-1) y las
cuales son por lo tanto útiles en el tratamiento de ciertos
trastornos que pueden prevenirse o tratarse por medio de la
inhibición de esta enzima. Además, la invención se
relaciona a compuestos, métodos para su preparación,
10 composiciones farmacéuticas que contienen los compuestos y
los usos de estos compuestos en el tratamiento de ciertos
trastornos. Se espera que los compuestos de la invención
encontrará aplicación en el tratamiento de condiciones
tales como diabetes mellitus tipo 2 no dependiente a la
15 insulina (NIDDM), resistencia a la insulina, obesidad,
glucosa en ayuno disminuida, tolerancia a la glucosa
disminuida, trastornos de lípidos tales como dislipidemia,
hipertensión y así como otras enfermedades y condiciones.

20

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800.176.089-2

-/-



RECIBO DE CAJA

No. 14 - 0076794

Bogotá D.C., Julio 22 de 2014 - 08:22:43

RECIBIDO DE : TOBOS ABOGADOS SAS

NI 900.367.556

RE

*** Soporte del Pago ***

TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	VR. PAGO
CONSIGNACION	BANCO DE BOGOTA	062754387	559294352	22/07/2014	21.000.00
CONSIGNACION	BANCO DE BOGOTA	062754387	559294396	22/07/2014	128.000.00

*** Conceptos Pagados ***

CANT.	RENTISTICO	CONCEPTO	Vr.UNDITARIO	Vr.CONCEPTO
1	50005-01-03 CAMBIO DE MODALIDAD Y MODIFICACIONES EN CREACION CORRECCION A SOLICITUD EN TRAMITE / MODIFICA		128.000.00	128.000.00
				<u>\$128.000.00</u>

SON: **CIENTO VEINTIOCHO MIL PESOS MONEDA CORRIENTE***

Responsable:

Recibo de Caja Aplicado al Expediente No. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 14-158010-00001-0000

Fecha: 2014-07-22 09:26:33 Dep. 2020 DIR.NUEVASCR
 Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
 Act. 608 MODIFICASOLICIT Folios: 47

Sede Centro: Carrera 13 No. 27 - 00 Pisos 3,4,5 y 10 Bogotá, D.C.- Colombia

Web: www.sic.gov.co e-mail: info@sic.gov.co Conmutador: (571) 5870000 Fax: (571) 5870284 Línea: 018000-910165 Call Center: (571) 6513240

, Julio 22 de 2014 - 08:22:44

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800.176.089-2

-/-



Industria y Comercio
SUPERINTENDENCIA

RECIBO DE CAJA

No. 14 - 0076797

Bogotá D.C., Julio 22 de 2014 - 08:24:40

RECIBIDO DE : TOBOS ABOGADOS SAS

NI 900.367.556

RE

*** Soporte del Pago ***

TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	VR PAGO
CONSIGNACION	BANCO DE BOGOTA	062754387	559294363	22/07/2014	806.000.00
CONSIGNACION	BANCO DE BOGOTA	062754387	559294400	22/07/2014	496.000.00

*** Conceptos Pagados ***

CANT. RENTISTICO	CONCEPTO	Vr.UNDITARIO	Vr.CONCEPTO
16 50005-01-01 SOLICITUDES	1607 REIVINDICACION PATENTE UNITARIA ADICIONAL A LAS 10 INIC	31.000.00	496.000.00
			<u>\$496.000.00</u>

SON: **CUATROCIENTOS NOVENTA Y SEIS MIL PESOS MONEDA CORRIENTE***

Responsable: _____

-*****-

Recibo de Caja Aplicado al Expediente No. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 14-158010- 00001-0000

Fecha: 2014-07-22 09:26:33 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 608 MODIFICASOLICIT Folios: 47

Sede Centro: Carrera 13 No. 27 - 00 Pisos 3,4,5 y 10 Bogotá, D.C.- Colombia

Web: www.sic.gov.co e-mail: info@sic.gov.co Conmutador: (571) 5870000 Fax: (571) 5870284 Línea: 018000-910165 Call Center: (571) 6513240

, Julio 22 de 2014 - 08:24:40

		PLANILLA DE RADICACIÓN - DIGITALIZACIÓN DIARIA RELACIÓN DE ANEXOS	
Dependencia: 2020		Fecha: ____/____/____ AAAA MM DD 2014 7 22	
Tipo de Radicación: Entrada: ☐ Salida: ☐ Traslado: ☐ Convenio: ☐		Recorrido:	
Radicador:		Planilla:	

ID	No. Radicación	Consecutivo	Item
1	14 - 158010 - 1		7
2			
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			

Item	Unidad de Conservación
1	Bolsa
2	Caja
3	Libro
4	Sobre
5	Tomo
6	Otro
Item	Soporte Documental
7	CD
8	Disquete
9	DVD
10	Folleto
11	Foto
12	Periódico
13	Plano
14	Publicación Periódica
15	USB
16	Otro

Observaciones: Folio (47) el cd anexo contiene un total de (2) archivos en formato pdf, los cuales fueron procesados correctamente.
--



DIRECCIÓN DE NUEVAS CREACIONES
MODIFICACIONES Y/O CORRECCIONES

1. Identificación del Trámite
- ☐ Error material
- ☒ Modificación a una Solicitud en trámite
- ☒ Patente de Invención
- ☐ Patente de Modelo de Utilidad
- ☐ Registro de Diseño Industrial
- ☐ Esquema de Trazado de Circuitos Integrados

2. Datos del solicitante
- Persona Natural ☐ Persona Jurídica ☒
- CONNEXIOS LIFE SCIENCES PVT. LTD.
- Nombre o denominación / Nombre o razón social completa
- Nombre representante legal
- Tipo de empresa Micro ☐ Pequeña ☐ Mediana ☐ Otra ☒
- Documento de identificación: ☐ C.C. ☐ C.E. ☐ NIT ☒ Otro Número

Nacionalidad/País de constitución	Dirección y domicilio del titular	Ciudad
India	No.49, Shilpa Vidya, First Main Road, J P Nagar 3rd Phase	Bangalore
Dirección electrónica	No. Fax	Número telefónico
tobos@tobos.com.co	571 8123335	571 8123335

☒ Autorizo expresamente a la Superintendencia de Industria y Comercio para que todas las comunicaciones sean enviadas a través de la dirección de correo electrónico

3. Datos del apoderado:
- TOBOS MATEUS Andrea
- 52.223.325
- 148.648
- Apellidos y Nombre
- Documento de identificación
- Tarjeta profesional

Dirección y domicilio		Ciudad
Carrera 7 C No. 138 -19 Oficina 901		Bogotá, D.C. Colombia
Dirección electrónica	No. Fax	Número telefónico
andrea.tobos@tobos.com.co	571 8123335	571 8123335

En caso de haber presentado poder general para asuntos que se adelanten ante la Delegatura de Propiedad Industrial, sírvase indicar el número de su radicación o protocolo de poder general

4. Datos del trámite

Corrección:

Expediente No

Aparece

Debe ser

Modificación:

☒ **Modificación al capítulo reivindicatorio.**
El solicitante desea limitar el Capítulo Reivindicatorio de 30 reivindicaciones a 26 reivindicaciones.

☐ **Modificación al capítulo descriptivo.**

☐ **Modificación al resumen.**

☐ **Modificación a los dibujos.**

☐ **Modificación al solicitante.**

5. Anexos

☒ Comprobante de pago de la tasa para la presentación de la corrección y/o modificación

☐ Poder, si fuere el caso.

☐ Documento que contiene las modificaciones o correcciones.

☐ Copia de la solicitud y sus anexos en formato magnético.

6. Firma

ANDREA TOBOS MATEUS

Nombre y apellidos


C.C 52.223.325

Firma

Tarjeta Profesional 148.648

REIVINDICACIONES

1. Un compuesto de la fórmula (I):




Fórmula (I)

caracterizado porque:


cada R^1 y R^{1a} es independientemente seleccionado del grupo que consiste de H, metilo, $\text{CONHC}(\text{CH}_3)_3$, OH, CO_2H , CO_2CH_3 , $\text{CO}_2\text{CH}_2\text{CH}_3$, fenilo, CH_2OH , CN y OCH_3 .

o cualquiera dos R^1 en átomos de carbono adyacentes se puede unir para formar una fracción cíclica, o cualquiera dos R^1 en el mismo carbono cuando se toman juntos pueden formar un grupo de la fórmula $=\text{O}$.

Ar es una opcionalmente sustituida por grupo c1-C_{18} heteroarilo;



Y



5 en donde cada R^7 es independientemente
 seleccionado del grupo que consiste H, halógeno, OH, NO₂,
 CN, SH, NH₂, CF₃, OCF₃, opcionalmente sustituido C₁-
 C₁₂alquilo, opcionalmente sustituido C₁-C₁₂haloalquilo,
 10 opcionalmente sustituido C₂-C₁₂alquenilo, opcionalmente
 sustituido C₂-C₁₂alquinilo, opcionalmente sustituido C₂-
 C₁₂heteroalquilo, opcionalmente sustituido C₃-
 C₁₂cicloalquilo, opcionalmente sustituido C₃-
 C₁₂cicloalquenilo, opcionalmente sustituido C₂-
 15 C₁₂heterocicloalquilo, opcionalmente sustituido C₂-
 C₁₂heterocicloalquenilo, opcionalmente sustituido C₆-
 C₁₈arilo, opcionalmente sustituido C₁- C₁₈heteroarilo,
 opcionalmente sustituido C₁-C₁₂alquiloxi, opcionalmente
 sustituido C₂-C₁₂alquenilooxi, opcionalmente sustituido C₂-
 20 C₁₂alquinilooxi, opcionalmente sustituido C₂-
 C₁₀heteroalquiloxi, opcionalmente sustituido C₃-
 C₁₂cicloalquiloxi, opcionalmente sustituido C₃-
 C₁₂cicloalquenilooxi, opcionalmente sustituido C₂-
 C₁₂heterocicloalquiloxi, opcionalmente sustituido C₂-C₁₂
 heterocicloalquenilooxi, opcionalmente sustituido C₆-
 25 C₁₈arilooxi, opcionalmente sustituido C₁-C₁ heteroarilooxi,

opcionalmente sustituido C₁-C₁₂alquiloamino, SR⁹, SO₃H, SO₂NR⁹R¹⁰, SO₂R⁹, SONR⁹R¹⁰, SOR⁹, COR⁹, COOH, COOR⁹, CONR⁹R¹⁰, NR⁹COR¹⁰, NR⁹COOR¹⁰, NR⁹SO₂R¹⁰, NR⁹CONR⁹R¹⁰, NR⁹R¹⁰, y acil;

5 en donde R⁸ es seleccionado del grupo que
consiste en H, opcionalmente sustituido C₁- C₁₂alquilo,
opcionalmente sustituido C₂-C₁₂alquenilo, opcionalmente
sustituido C₂-C₁₂alquinilo, opcionalmente sustituido C₂-
C₁₂heteroalquilo, opcionalmente sustituido C₃-
C₁₂cicloalquilo, opcionalmente sustituido C₂-
10 C₁₂heterocicloalquilo, opcionalmente sustituido C₆-C₁₈arilo,
opcionalmente sustituido C₁- C₁₈heteroarilo, SO₃H, SO₂NR⁹R¹⁰,
SO₂R⁹, SONR⁹R¹⁰, SOR⁹, COR⁹, COOH, COOR⁹, y CONR⁹R¹⁰;

 en donde cada R⁹ y R¹⁰ es independientemente
seleccionado del grupo que consiste en H, opcionalmente
15 sustituido C₁-C₁₂alquilo, opcionalmente sustituido C₂-
C₁₀heteroalquilo, opcionalmente sustituido C₁-C₁₂haloalquilo,
opcionalmente sustituido C₃-C₁₂cicloalquilo, opcionalmente
sustituido C₆- C₁₈arilo, y opcionalmente sustituido C₁-
C₁₈heteroarilo.

20 e es un entero seleccionado del grupo que
consiste de 0, 1, 2, 3 y 4;

 f es un entero seleccionado del grupo que
consiste de 0, 1, 2, y 3;

25

A es $-\text{CR}^a\text{R}^b-$;

B es un grupo de la fórmula $-(\text{CR}^c\text{R}^d)_n-$;

5 en donde cada R^a , R^b , R^c y R^d es
independientemente seleccionado del grupo que consiste en
H, halógeno, OH, NO_2 , CN, SH, NH_2 , CF_3 , OCF_3 , opcionalmente
sustituido C_1 - C_{12} alquilo, opcionalmente sustituido C_2 -
 C_{10} heteroalquilo, opcionalmente sustituido C_1 - C_{12} haloalquilo,
opcionalmente sustituido C_3 - C_{12} cicloalquilo, opcionalmente
sustituido C_6 - C_{18} arilo, opcionalmente sustituido C_1 -
10 C_{18} heteroarilo; SR^2 , SO_3H , $\text{SO}_2\text{NR}^2\text{R}^3$, SO_2R^2 , SONR^2R^3 , SOR^2 ,
 COR^2 , COOH , COOR^2 , CONR^2R^3 , NR^2COR^3 , NR^2COOR^3 , $\text{NR}^2\text{SO}_2\text{R}^3$,
 $\text{NR}^2\text{CONR}^2\text{R}^3$, NR^2R^3 , y acil,

15 en donde cada R^2 y R^3 es independientemente
seleccionado del grupo que consiste en H, opcionalmente
sustituido C_1 - C_{12} alquilo, opcionalmente sustituido C_2 -
 C_{10} heteroalquilo, opcionalmente sustituido C_1 - C_{12} haloalquilo,
opcionalmente sustituido C_3 - C_{12} cicloalquilo, opcionalmente
sustituido C_6 - C_{18} arilo, y opcionalmente sustituido C_1 -
 C_{18} heteroarilo;

20 W^1 y W^2 están seleccionados de tal forma que uno
es N y el otro es (CR^1_2) ,

el enlace del carbono carbonil se une a
cualquiera de W^1 o W^2 es N;

D es O o (CR^1_2) ;

n es un entero seleccionado del grupo que
consiste de 0, 1, 2, 3, y 4;

a es un entero seleccionado del grupo que
consiste de 0, 1, y 2;

5

b es un entero seleccionado del grupo que
consiste de 0, 1, 2, 3, 4, 5, 6, 7, y 8,

c es 1;

o una sal farmacéuticamente aceptable de los
mismos.

10

2. Un compuesto de conformidad con la
reivindicación 1, caracterizado porque D es (CR^{1_2}) .


3. Un compuesto de conformidad con la
reivindicación 1, caracterizado porque B es CH_2 .

15

4. Un compuesto de conformidad con la
reivindicación 1 a 3, caracterizado porque R^a y R^b son
diferentes.

5. Un compuesto de conformidad con la
reivindicación 1 que tiene la fórmula:

20



25

en donde Ar, R^a, R^b, R¹, R^{1a}, a y b son como se definen en la reivindicación 1.


6. Un compuesto de conformidad con la reivindicación 5, en donde uno de R^a y R^b es H y el otro es alquilo opcionalmente sustituido.

7. Un compuesto de conformidad con la reivindicación 1, caracterizado porque el sustituyente R⁷ está ubicado en la posición 4 o en la posición 5 del anillo de seis miembros.

8. Un compuesto de conformidad con la reivindicación 1, caracterizado porque R⁷ se selecciona del grupo que consiste de CH₃, CH₂CH₃, CH₂CH₂CH₃, CH(CH₃)₂, (CH₂)₃CH₃, Cl, Br, F, I OH, NO₂, NH₂, CN, SO₃H, OCH₃, OCH₂CH₂CH₃, CF₃ y OCF₃.



9. Un compuesto de conformidad con la reivindicación 1, seleccionado del grupo que consiste en:

20





25



5





10



15





20





25



5





10



15




20




25


5




10







15




20




25





5





10




15





20





25





5





10





15





20





25





5





10





15





20





25





5





10



15





20





25




5





10



15





20





25







5







10




15





20





25





5





10







15





20





25





5





10




15





20





25





5







10




15





20





25





5





10





15





20





25





5





10







15





20







25







5





10





15





20







25







5







10



15







20







25





5





10



15





20





25



5







10





15




20





25











5







10




15





20









25







5





10



15







20







25





5





10



15







20







25





5





10



15





20







25





5





10



15





20





25



5





10







15




20





25









5





10







15





20





25





5





10



15





20





25



5







10





15




20



25





15 o su sal farmacéuticamente aceptable.

10. Una composición farmacéutica que incluye un
compuesto de conformidad con cualquiera de las
reivindicaciones 1 a 9 y un diluyente, excipiente o
20 vehículo farmacéuticamente aceptable.

11. Un método para la prevención o tratamiento
de una condición en un mamífero, el método comprendiendo la
administración de una cantidad efectiva de un compuesto de
conformidad con cualquiera de las reivindicaciones 1 a 9.

25 12. Un método de conformidad con la

reivindicación 11, caracterizado porque la condición puede ser prevenida o tratada por la inhibición de 11 β -HSD1.

5 13. Un método de conformidad con la reivindicación 12, caracterizado porque la condición se selecciona del grupo que consiste de diabetes, hiperglucemia, baja tolerancia a la glucosa, hiperinsulinemia, hiperlipidemia, hipertrigliceridemia, hipercolesterolemia, dislipidemia, obesidad, obesidad abdominal, glaucoma, hipertensión, aterosclerosis y sus
10 secuelas, retinopatía, nefropatía, neuropatía, miopatía, osteoporosis, osteoartritis, demencia, depresión, enfermedades neurodegenerativas, trastornos psiquiátricos, Enfermedad de Cushing, síndrome de Cushing, enfermedades virales, y enfermedades inflamatorias.

15 14. Un método de conformidad con la reivindicación 13, caracterizado porque la condición es diabetes.

20 15. Un método de conformidad con la reivindicación 14, caracterizado porque la condición es diabetes tipo II.

 16. El método de conformidad con la reivindicación 12, caracterizado porque el compuesto se administra en combinación con un adyuvante.

25 17. El método de conformidad con la reivindicación 16, caracterizado porque el adyuvante es

seleccionado del grupo que consiste de dipeptidil
peptidasa-IV (DP-IV); (b) agentes sensibilizantes de
insulina; (c) insulina y miméticos de insulina; (d)
sulfonilureas y otros secretagogos de insulina; (e)
5 inhibidores alfa-glucosidasa; (f) GLP-1, análogos GLP-1, y
agonistas receptores de GLP-1; y las combinaciones de los
mismos.

18. El método de conformidad con la
reivindicación 17, caracterizado porque los agentes
10 sensibilizantes de insulina son seleccionados del grupo que
consiste en (i) PPAR-gamma-agonistas, (ii) PPAR-alfa-
agonistas, (iii) PPAR-alfa/gamma-dual agonistas, (iv)
biguanidas, y combinaciones de los mismos.

19. El uso de un compuesto de conformidad con la
15 reivindicación 1 en la preparación de un medicamento.

20. El uso de conformidad con la reivindicación
19, caracterizado porque el medicamento es para el
tratamiento de una condición que se puede prevenir o tratar
por la inhibición de 11 β -HSD1.

21. El uso de conformidad con la reivindicación
20, caracterizado porque la condición se selecciona del
grupo que consiste de diabetes, hiperglucemia, baja
tolerancia a la glucosa, hiperinsulinemia, hiperlipidemia,
hipertrigliceridemia, hipercolesterolemia, dislipidemia,
25 obesidad, obesidad abdominal, glaucoma, hipertensión,

aterosclerosis y sus secuelas, retinopatía, nefropatía, neuropatía, miopatía, osteoporosis, osteoartritis, demencia, depresión, enfermedades neurodegenerativa, trastornos psiquiátricos, Enfermedad de Cushing, síndrome
5 de Cushing, enfermedades virales, y enfermedades inflamatorias.

22. Un uso de conformidad con la reivindicación 21, caracterizado porque la condición es diabetes.

23. Un uso de conformidad con la reivindicación
10 22, caracterizado porque la condición es diabetes tipo II.

24. Un uso de conformidad con la reivindicación 22 ó 23, caracterizado porque el medicamento contiene un adyuvante.

25. Un uso de conformidad con la reivindicación
15 24, caracterizado porque el adyuvante es seleccionado del grupo que consiste de dipeptidil peptidasa-IV (DP-IV); (b) agentes sensibilizantes de insulina; (c) insulina y miméticos de insulina; (d) sulfonilureas y otros secretagogos de insulina; (e) inhibidores alfa-glucosidasa;
20 (f) GLP-1, análogos GLP-1, y agonistas receptores de GLP-1; y las combinaciones de los mismos.

26. El uso de conformidad con la reivindicación 25, caracterizado porque los agentes sensibilizantes de insulina son seleccionados del grupo que consiste en (i)
25 PPAR-gamma-agonistas, (ii) PPAR-alfa-agonistas, (iii) PPAR-

alfa/gamma-dual agonistas, (iv) biguanidas, y combinaciones de los mismos.

RESUMEN

La presente invención se relaciona a ciertos derivados de amida que tienen la capacidad para inhibir 11-
5 β -hidroxiesteroide deshidrogenasa tipo 1 (11 β -HSD-1) y las cuales son por lo tanto útiles en el tratamiento de ciertos trastornos que pueden prevenirse o tratarse por medio de la inhibición de esta enzima. Además, la invención se relaciona a compuestos, métodos para su preparación,
10 composiciones farmacéuticas que contienen los compuestos y los usos de estos compuestos en el tratamiento de ciertos trastornos. Se espera que los compuestos de la invención encontrará aplicación en el tratamiento de condiciones tales como diabetes mellitus tipo 2 no dependiente a la
15 insulina (NIDDM), resistencia a la insulina, obesidad, glucosa en ayuno disminuida, tolerancia a la glucosa disminuida, trastornos de lípidos tales como dislipidemia, hipertensión y así como otras enfermedades y condiciones.